US 5,847,135 A · Inhibitors of interleukin-1.beta. converting enzyme

Abstract

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1.beta. converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

A compound represented by the formula:

##STR166## wherein:
X.sub.1 is CH or N;
g is 0 or 1;
each J is independently selected from the group consisting of --H, --OH, and --F, provided that when a first and second J are bound to a C and said first J is --OH, said second J is --H;
m is 0, 1, or 2;
T is --Ar.sub.3, --OH, --CF.sub.3, --CO--CO.sub.2 H, or --CO.sub.2 H;
R.sub.1 is selected from the group consisting formulae, in which any ring is optionally singly or multiply substituted at any carbon by Q.sub.1, at any nitrogen by R.sub.5, and in which any saturated ring is optionally unsaturated at one or two bonds:
##STR167## wherein ring C is benzo, pyrido, thieno, pyrrolo, furano, thiazolo, isothiazolo, oxazolo, isoxazolo, pyrimido, imidazolo, cyclopentyl, or cyclohexyl;
provided that when:
X.sub.1 is CH;
and
T is --OH --CO--CO.sub.2 H, or --CO.sub.2 H;
R.sub.1 is not:
##STR168## R.sub.3 is --CN,
--CH.dbd.CH--R.sub.9,
--CH.dbd.N--O--R.sub.9,
--(CH.sub.2).sub.1-3 --T.sub.1 --R.sub.9,
--CJ.sub.2 --R.sub.9,
--CO--R.sub.13, or ##STR169## each R.sub.13 is independently R.sub.4 or AR.sub.2, each R.sub.4 is independently:
--H,
--AR.sub.1
--R.sub.9
--T.sub.1 --R.sub.9, or
--(CH.sub.2).sub.1,2,3 --T.sub.1 --R.sub.9 ;
each T.sub.1 is independently
--CH.dbd.CH--,
--O--,
--S--,
--SO--,
--SO.sub.2 --,
--NR.sub.10 --,
--NR.sub.10 --CO--,
--CO--,
--O--CO--,
--CO--O--,
--CO--NR.sub.10 --,
--NR.sub.10 --CO--O--,
--NR.sub.10 --CO--NR.sub.10 --,
--SO.sub.2 --NR.sub.10 --,
--NR.sub.10 --SO.sub.2 --, or
--NR.sub.10 --SO.sub.2 --NR.sub.10 --;
each R.sub.5 is independently
--H,
--Ar.sub.1,
--CO--Ar.sub.1,
--SO.sub.2 --Ar.sub.1,
--R.sub.9,
--CO--R.sub.9,
--CO--O--R.sub.9,
--SO.sub.2 --R.sub.9, ##STR170## R.sub.6 and R.sub.7 taken together form a saturated 4-8 member carbocyclic ring or heterocyclic ring containing --O--, --S--, or --NH--, or R.sub.7 is --H and R.sub.6 is
--H,
--AR.sub.1,
--R.sub.9, or
--(CH.sub.2).sub.1,2,3 --T.sub.1 --R.sub.9,
each R.sub.9 is a C.sub.1-6 straight or branched alkyl group optionally singly or multiply substituted by --OH, --F, or .dbd.O and optionally substituted with one or two Ar.sub.1 groups;
each R.sub.10 is independently --H or a C.sub.1-6 straight or branched alkyl group;
each Ar.sub.1 is a cyclic group independently selected from an aryl group which contains 6, 10, 12, or 14 carbon atoms and between 1 and 3 rings, a cycloalkyl group which contains between and 3 and 15 carbon atoms and between 1 and 3 rings, said cycloalkyl group being optionally benzofused, or a heterocycle group containing between 5 and 15 ring atoms and between 1 and 3 rings, said heterocycle group containing at least one heteroatom selected from --O--, --S--, --SO--, --SO.sub.2 --, .dbd.N--, and --NH--, said heterocycle group optionally containing one or more double bonds, said heterocycle group optionally comprising one or more aromatic rings, and said cyclic group optionally being singly or multiply substituted by .dbd.O, --OH, perfluoro C.sub.1-3 alkyl, or --Q.sub.1 ;
each Ar.sub.2 is independently selected from the following group, in which any ring is optionally substituted by --Q.sub.1 :
##STR171## Ar.sub.3 is a cyclic group selected from a phenyl ring, a 5-membered heteroaromatic rings, or a 6-membered heteroaromatic ring, said heteroaromatic rings comprising 1-3 heteroatom groups selected from --O--, --S--, --SO--, --SO.sub.2 --, .dbd.N--, and --NH--, said cyclic group optionally being singly or multiply substituted with .dbd.O, --OH, halogen, perfluoro C.sub.1-3 alkyl, or --CO.sub.2 H:
each Q.sub.1 is independently;
--Ar.sub.1,
--R.sub.9,
--T.sub.1 --R.sub.9, or
--(CH.sub.2).sub.1,2,3 --T.sub.1 --R.sub.9 ;
provided that when --Ar.sub.1 is substituted with a Q.sub.1 group which comprises one or more additional --Ar.sub.1 groups, said additional --Ar.sub.1, groups are not substituted with Q.sub.1 ;
each X is independently .dbd.N-- or .dbd.CH--;
X.sub.2 is --O--, --CH.sub.2 --, --NH--, --S--, --SO--, or --SO.sub.2 --;
X.sub.4 is --CH.sub.2 -- or --NH--;
each Y is independently selected from the group consisting of --O-- and --S--;
each Z is independently CO or SO.sub.2,
a is 0 or 1,
c is 1 or 2, and
each d is independently 0, 1, or 2.

70 more elements

Inhibitors of interleukin-1.beta. converting enzyme

Life of this patent

Inhibitors of interleukin-1.beta. converting enzyme

Life of this patent

Abstract

Claims11